The FDA approved 16 psychiatric drugs over the last decade, most of which shared similar mechanisms of action with previously ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

TrialWire, a leader in clinical trial recruitment innovation, launched its groundbreaking AI Voice Screen service as part of the TrialWire Recruitment Platform powered by Salesforce Health Cloud, ...

Correspondence to Dr Thomas Bandholm, Dept of Clinical Research ... time concise and describe the knowledge gap that your trial is intended to fill. Your introduction should present the scientific ...

The inauguration of a new administration in the White House heralds a consequential juncture for women’s health globally.

Laurie Adami's experience with CAR T-cell therapy highlights its potential in treating Non-Hodgkin Lymphoma, emphasizing the ...

While many brands borrow scientific language to reinforce claims, Noble Panacea is rooted in molecular chemistry, delivering ...

Exclusive: The puberty blockers trial is due to start within the next few weeks, The Independent understands, but the government is yet to communicate plans for the trial with the young people who wil ...

Objectives This study evaluated the representation of black researchers as authors of articles published in four ...

Ugandan authorities on Monday began a clinical trial of a vaccine against the Sudan strain of Ebola that has killed one ...

Flicking through medical textbooks in 2022, our team spotted a surprising omission: a stark absence of images of health conditions on darker skin tones.

Cortigent, Inc. (CRTG) expects to raise $15 million in an initial public offering (IPO) on Friday, February 14th, IPO Scoop reports. The company will be issuing 1,500,000 shares at $10.00 per share.